Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

ties, and investments to build greater breadth and capacity to support Schering-Plough's expanding R&D pipeline.

Acquired in-process research and development, a charge related to the purchase accounting of the OBS acquisition, totaled $3.8 billion for the fourth quarter of 2007.

Full-Year 2007 Results

For the full-year 2007, Schering-Plough reported a net loss available to common shareholders of $1.6 billion or $1.04 per common share on a GAAP basis due to purchase accounting adjustments. Earnings per common share would have been $1.37, excluding purchase accounting adjustments, acquisition-related items and other specified items (see table below on page 15). For the full- year 2006, Schering-Plough reported net income of $1.1 billion or 71 cents per common share on a GAAP basis and 87 cents per common share excluding other specified items.

Schering-Plough reported full-year 2007 GAAP net sales of $12.7 billion, a 20 percent increase, compared to $10.6 billion in 2006. Full-year 2007 net sales included $626 million of OBS net sales related to the period subsequent to the acquisition. In addition, the sales growth reflects a 4 percent favorable impact from foreign exchange. Schering-Plough's adjusted sales for 2007 totaled $15.2 billion, an increase of $2.7 billion as compared to $12.5 billion on an adjusted basis in 2006.

On a GAAP basis, Schering-Plough's gross margin was 65.3 percent in 2007 as compared to 65.1 percent in 2006. The gross margin percentage excluding purchase accounting adjustments and other specified items increased to 67.9 percent in 2007 as compared to 66.5 percent in 2006, due primarily to realized cost savings in 2007 from manufacturing streamlining activities during 2006.

Selling, general and administrative expenses were $5.5 billion for the 2007 full year. Research and development spending for 2007 totaled $2.9 billion. Full-year 2007 results include results of operations for OBS for the period subseq
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Ill. , July 23, 2014 /PRNewswire/ ... (SNA™) constructs as gene regulatory and immunotherapeutic ... has joined AuraSense Therapeutics, executive leadership ... 11. Prior to joining AuraSense ... and Chief Financial Officer of Cellular Dynamics ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
(Date:7/23/2014)... 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that the underwriters of its common ... purchase an additional 420,000 shares of common stock ... share, less underwriting discounts and commissions, in connection ... 2,800,000 shares of common stock, bringing the expected ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... industrial design at the Milwaukee Institute of Art and ... will assist people with spinal damage with their toileting activities. ... are paralyzed from the neck or the waist down can ... moving their bowels. Since they have no sensation in the ...
... , Milwaukee OnCourse Technologies , a ... have signed a term sheet to sell two subsidiaries to ... are involved in CAD/CAM technology: TekSoft creates the ... and distributor of related products. The deal is expected to ...
... researchers have put enough monitoring equipment on a bicycle to ... soap bubbles, and found losing sleep makes you hungry. Interested? ... ,Put a GPS monitor on a bicycle, add devices ... and rhythm created by their peddling, record it all at ...
Cached Biology Technology:This wheelchair will save lives 2This wheelchair will save lives 3Tech Digest: OnCourse, Menasha, Fiserv, Rockwell 2A week in UW research: fusion, racing and sleep 2A week in UW research: fusion, racing and sleep 3
(Date:7/23/2014)... -- The potential for clinical use of induced ... strategies has previously been hindered by the risk ... tumors. The ability to use etoposide treatment to ... of heart disease, specifically acute myocardial infarction, is ... and Development , a peer-reviewed journal from Mary ...
(Date:7/23/2014)... mollusks, starfish, and corals have in common? Aside ... calcifiersorganisms that use calcium from their environment to ... and protection. , The July issue of ... Biological Laboratory, addresses the challenges faced by these ... atmospheric carbon dioxide rises, the world,s oceans are ...
(Date:7/23/2014)... -- BCC Research ( www.bccresearch.com ... AND TECHNOLOGIES FOR SENSORS , the global market for ... nearly $154.4 billion by 2020, with a five-year compound ... and level sensors segment is moving at a significant ... , Sensors have become indispensable to many ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... six-month study by Iowa State University researchers had indicated ... isoflavones, lessened lumbar spine bone loss in midlife, perimenopausal ... of those same researchers does not show a bone-sparing ... except for a modest effect at the femoral (hip) ...
... 5, 2010) New research from the Hood Center for Children ... time sheds light on the significant potential negative impact that ... children. The study, which appears in the current edition ... the "brand placements" for food, beverage, and food retail establishments ...
... ( T. gondii ) is considered as one of the ... wide range of intermediate hosts, including all mammals and birds. ... and 20% in the world are chronically infected. ... now accepting applications for its Investigative Workshop, Modeling Toxoplasma ...
Cached Biology News:Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 3New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3Modeling Toxoplasma focus of workshop 2
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: